Literature DB >> 19362970

Cytokines in the microenvironment of Waldenström's macroglobulinemia.

Sherine F Elsawa1, Stephen M Ansell.   

Abstract

Waldenström's macroglobulinemia (WM) is a lymphoplasmacytic lymphoma characterized by the overproduction of a monoclonal IgM protein that accumulates in the serum. Although the pathologic findings in this disease entity are reasonably well defined, the mechanisms that regulate malignant B-cell growth and monoclonal protein synthesis are less well understood. Cytokines are known to regulate many biologic processes in normal lymphocyte development including immunoglobulin production, and the presence of cytokines within the tumor microenvironment of WM is likely to contribute to malignant cell growth and survival as well as immunoglobulin production. Several studies have suggested that cytokines are potentially dysregulated in WM, however the precise role played by cytokines in WM biology is not clearly defined. This report therefore highlights our current understanding of the role of cytokines in the microenvironment of WM and how they affect malignant cell persistence and function in the bone marrow of patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19362970      PMCID: PMC3632213          DOI: 10.3816/CLM.2009.n.010

Source DB:  PubMed          Journal:  Clin Lymphoma Myeloma        ISSN: 1557-9190


  25 in total

1.  Mast cells in Waldenstrom's macroglobulinemia support lymphoplasmacytic cell growth through CD154/CD40 signaling.

Authors:  O Tournilhac; D D Santos; L Xu; J Kutok; Y-T Tai; S Le Gouill; L Catley; Z Hunter; A R Branagan; J A Boyce; N Munshi; K C Anderson; S P Treon
Journal:  Ann Oncol       Date:  2006-06-20       Impact factor: 32.976

Review 2.  Microenvironmental niches in the bone marrow required for B-cell development.

Authors:  Takashi Nagasawa
Journal:  Nat Rev Immunol       Date:  2006-02       Impact factor: 53.106

3.  SDF-1/CXCR4 and VLA-4 interaction regulates homing in Waldenstrom macroglobulinemia.

Authors:  Hai T Ngo; Xavier Leleu; Jack Lee; Xiaoying Jia; Molly Melhem; Judith Runnels; Anne-Sophie Moreau; Nicholas Burwick; Abdel Kareem Azab; Aldo Roccaro; Feda Azab; Antonio Sacco; Mena Farag; Robert Sackstein; Irene M Ghobrial
Journal:  Blood       Date:  2008-04-30       Impact factor: 22.113

4.  B-lymphocyte stimulator (BLyS) stimulates immunoglobulin production and malignant B-cell growth in Waldenstrom macroglobulinemia.

Authors:  Sherine F Elsawa; Anne J Novak; Deanna M Grote; Steven C Ziesmer; Thomas E Witzig; Robert A Kyle; Stacey R Dillon; Brandon Harder; Jane A Gross; Stephen M Ansell
Journal:  Blood       Date:  2005-11-22       Impact factor: 22.113

5.  Gene-expression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma.

Authors:  Wee J Chng; Roelandt F Schop; Tammy Price-Troska; Irene Ghobrial; Neil Kay; Diane F Jelinek; Morie A Gertz; Angela Dispenzieri; Martha Lacy; Robert A Kyle; Philip R Greipp; Renee C Tschumper; Rafael Fonseca; Peter Leif Bergsagel
Journal:  Blood       Date:  2006-06-27       Impact factor: 22.113

6.  Abnormal bone remodelling and increased levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) in Waldenström macroglobulinaemia.

Authors:  Evangelos Terpos; Athanasios Anagnostopoulos; Efstathios Kastritis; Aristotelis Bamias; Konstantinos Tsionos; Meletios-Athanassios Dimopoulos
Journal:  Br J Haematol       Date:  2006-05       Impact factor: 6.998

Review 7.  Monoclonal gammopathies of undetermined significance.

Authors:  Robert A Kyle; S Vincent Rajkumar
Journal:  Best Pract Res Clin Haematol       Date:  2005       Impact factor: 3.020

8.  Serum levels of inflammatory cytokines at diagnosis correlate to the bcl-6 and CD10 defined germinal centre (GC) phenotype and bcl-2 expression in patients with diffuse large B-cell lymphoma.

Authors:  Lars M Pedersen; Gitte W Jürgensen; Hans E Johnsen
Journal:  Br J Haematol       Date:  2005-03       Impact factor: 6.998

9.  Serum concentrations of angiogenic cytokines in Waldenstrom macroglobulinaemia: the ration of angiopoietin-1 to angiopoietin-2 and angiogenin correlate with disease severity.

Authors:  Athanasios Anagnostopoulos; Vangelis Eleftherakis-Papaiakovou; Efstathios Kastritis; Konstantinos Tsionos; Aristotelis Bamias; John Meletis; Meletios A Dimopoulos; Evangelos Terpos
Journal:  Br J Haematol       Date:  2007-06       Impact factor: 6.998

10.  Proteomic analysis of waldenstrom macroglobulinemia.

Authors:  Evdoxia Hatjiharissi; Hai Ngo; Alexey A Leontovich; Xavier Leleu; Michael Timm; Mona Melhem; Diane George; Ganwei Lu; Joanna Ghobrial; Yazan Alsayed; Steven Zeismer; Miguel Cabanela; Alex Nehme; Xiaoying Jia; Anne Sophie Moreau; Steven P Treon; Rafael Fonseca; Morie A Gertz; Kenneth C Anderson; Thomas E Witzig; Irene M Ghobrial
Journal:  Cancer Res       Date:  2007-04-15       Impact factor: 12.701

View more
  8 in total

1.  Comprehensive analysis of tumor microenvironment cytokines in Waldenstrom macroglobulinemia identifies CCL5 as a novel modulator of IL-6 activity.

Authors:  Sherine F Elsawa; Anne J Novak; Steven C Ziesmer; Luciana L Almada; Lucy S Hodge; Deanna M Grote; Thomas E Witzig; Martin E Fernandez-Zapico; Stephen M Ansell
Journal:  Blood       Date:  2011-09-14       Impact factor: 22.113

2.  GLI2 transcription factor mediates cytokine cross-talk in the tumor microenvironment.

Authors:  Sherine F Elsawa; Luciana L Almada; Steven C Ziesmer; Anne J Novak; Thomas E Witzig; Stephen M Ansell; Martin E Fernandez-Zapico
Journal:  J Biol Chem       Date:  2011-03-18       Impact factor: 5.157

3.  Novel Molecular Mechanism of Regulation of CD40 Ligand by the Transcription Factor GLI2.

Authors:  Weiguo Han; David A Jackson; Stephan J Matissek; Jason A Misurelli; Matthew S Neil; Brandon Sklavanitis; Nansalmaa Amarsaikhan; Sherine F Elsawa
Journal:  J Immunol       Date:  2017-05-01       Impact factor: 5.422

4.  Modulation of the IL-6 Receptor α Underlies GLI2-Mediated Regulation of Ig Secretion in Waldenström Macroglobulinemia Cells.

Authors:  David A Jackson; Timothy D Smith; Nansalmaa Amarsaikhan; Weiguo Han; Matthew S Neil; Shannon K Boi; Anne M Vrabel; Ezequiel J Tolosa; Luciana L Almada; Martin E Fernandez-Zapico; Sherine F Elsawa
Journal:  J Immunol       Date:  2015-08-03       Impact factor: 5.422

5.  Soluble PD-1 ligands regulate T-cell function in Waldenstrom macroglobulinemia.

Authors:  Shahrzad Jalali; Tammy Price-Troska; Jonas Paludo; Jose Villasboas; Hyo-Jin Kim; Zhi-Zhang Yang; Anne J Novak; Stephen M Ansell
Journal:  Blood Adv       Date:  2018-08-14

6.  Epigenetic targeting of Waldenström macroglobulinemia cells with BET inhibitors synergizes with BCL2 or histone deacetylase inhibition.

Authors:  Stephan J Matissek; Weiguo Han; Mona Karbalivand; Mohamed Sayed; Brendan M Reilly; Shayna Mallat; Shimaa M Ghazal; Manit Munshi; Guang Yang; Steven P Treon; Sarah R Walker; Sherine F Elsawa
Journal:  Epigenomics       Date:  2020-12-24       Impact factor: 4.778

7.  Targeting IL-6 receptor reduces IgM levels and tumor growth in Waldenström macroglobulinemia.

Authors:  Weiguo Han; Stephan J Matissek; David A Jackson; Brandon Sklavanitis; Sherine F Elsawa
Journal:  Oncotarget       Date:  2019-05-21

Review 8.  Waldenström Macroglobulinemia: Mechanisms of Disease Progression and Current Therapies.

Authors:  Ava J Boutilier; Lina Huang; Sherine F Elsawa
Journal:  Int J Mol Sci       Date:  2022-09-22       Impact factor: 6.208

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.